期刊文献+

非小细胞肺癌p53蛋白表达量及倍体测定与预后关系 被引量:4

The Relationship between the Expression and Ploidy of p53 and Prognosis in Non-small Cell Lung Cancer
下载PDF
导出
摘要 目的 通过非小细胞肺癌p53蛋白表达量及倍体测定,结合临床病理学特点,探讨患者预后的影响 因素。方法 应用流式细胞术检测120例非小细胞肺癌的p53蛋白表达量及DNA倍体。结果 淋巴结转移组 p53蛋白表达量高于无转移组,COX单因素分析表明,p53蛋白表达量、倍体及临床TNM分期均与预后有关,COX 多因素分析发现,仅p53蛋白表达量是独立的预后因素。结论 p53蛋白高表达可能是非小细胞肺癌患者预后不 良的主要因素之一。 Objective To study the expression and ploidy of p53 in non-small cell lung cancer (NSCLC) and the relationship between p53 protein and prognosis. Methods The expressive level and ploidy of p53 in 120 NSCLC samples were detected by flow cytometry method. Result P53 protein expressed much more in NSCLC with lymph metastasis than in NSCLC without lymph metastasis. COX univariate analysis showed that the expression and ploidy of p53 and TNM classification were related to the prognosis of NSCLC patients. COX multivariate analysis indicated that the expressive level of p53 was the only independent prognostic factor. Conclusion The expression of p53 might be a primary prognostic factor of NSCLC patients.
出处 《解剖科学进展》 CAS 2005年第1期25-26,共2页 Progress of Anatomical Sciences
基金 教育部留学回国人员科研基金(2002-247)
关键词 P53蛋白表达 非小细胞肺癌 DNA倍体 预后不良 COX 患者 预后因素 结论 主要因素 特点 non-small lung cancer p53 ploidy flow cytometry
  • 引文网络
  • 相关文献

参考文献5

  • 1左连富,齐风英,刘江惠,郭建文.乳腺癌P53基因蛋白的表达与临床预后的关系[J].癌症,1995,14(4):252-255. 被引量:13
  • 2Uicc TNM. Callification of malignant tumour [M]. 5ed New York:Wiley-Liss, 1997,93~97.
  • 3Fujino M, Dosaka-Akita H, Harada M, et al. Prognostic significance of p53 and p21 expression in non-small cell lung cancer [J].Cancer, 1995,76(12) :2457 ~2463.
  • 4Fu XL, Zhu XZ, Shi DR, et al. Study of prognostic predictors for non-small cell lung cancer [J]. Lung Cancer, 1999,23(2): 143 ~152.
  • 5Lee JS, Yoon A, Kalapurakal SK, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor [J]. J Clin Oncol, 1995,13(8):1893 ~1903.

共引文献12

同被引文献69

  • 1张喜梅,郭铁云,闫晓飞,陈雅隽,雷蕾,金连弘,池美花,张宝东.5-aza-dC和TSA对NIH/3T3细胞多能性基因表达作用的实验研究[J].解剖科学进展,2010,16(5):405-408. 被引量:6
  • 2张建,胡远兵,杨忠,蔡文琴.Wnt信号通路与神经发生[J].解剖科学进展,2005,11(3):258-260. 被引量:14
  • 3孔令亭,李若葆,王金平.吸烟与肺癌p53、K-ras基因突变关系及性别差异的研究进展[J].解剖科学进展,2006,12(3):275-278. 被引量:5
  • 4孔令亭,李若葆,王金平.突变型p53、VEGF在肺癌中的表达与预后的关系[J].解剖科学进展,2007,13(1):79-82. 被引量:5
  • 5Haeseleer F, Pollet JF, Bollen A, et al. Molecular cloning and sequencing of the attachment site and integrase gene of the temperate mycobacteriophage FRATI[J]. Nucleic Acids Res, 1992, 20: 1420.
  • 6Jonkers J, Korswagen HC, Acton D, et al. Activation of a novel proto- oncogene, Fratl, contributes to progression of mouse T-celllymphomas[J]. Embo J, 1997, 16: 441-450.
  • 7Yost C, Farr GH, Pierce SB, et al. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis[J]. Ce11,1998, 93: 1031-1041.
  • 8Hedgepeth CM, Deardorff MA, Rankin K, et al. Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin[J]. Mol Cell Biol, 1999, 19: 7147-7157.
  • 9Jonkers J, Weening J J, van der Valk M, et al. Overexpression of Fratl in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Fra! 1 in lymphoma progression[J]. Oncogene, 1999, 18: 5982-5990.
  • 10Thomas GM, Frame S, Goedert M, et al. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphory- lation of axin and beta-catenin[J]. FEBS Lett, 1999, 458:247-251.

引证文献4

二级引证文献3

;
使用帮助 返回顶部